Abciximab Readministration: Results of the ReoPro Readministration Registry
暂无分享,去创建一个
R. Jordan | M. Effron | A. Lincoff | J. Tcheng | M. Mascelli | N. Kleiman | D. Sane | D. Cines | D. Kereiakes | B. George | A. Schantz | G. Braden | M. A. Langrall | L. Damaraju | Mary Ann Langrall
[1] M. Madan,et al. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. , 1999, American heart journal.
[2] D. Mascarenhas,et al. Abciximab readministration: A single‐operator community‐hospital experience , 1999, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[3] E. Antman,et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. , 1999, Circulation.
[4] Y. Gruel,et al. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. , 1999, American journal of clinical pathology.
[5] David P Miller,et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. , 1998, Circulation.
[6] J. Tcheng,et al. Glycoprotein IIb/IIIa integrin blockade. , 1998, Circulation.
[7] E. Topol. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade , 1998, The Lancet.
[8] H. Weisman,et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. , 1998, Circulation.
[9] M. Pfisterer,et al. Safe use of platelet GP IIb/IIIa inhibitors. , 1998, American heart journal.
[10] Epilog Investigators,et al. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.
[11] R. Harrington,et al. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. , 1997, Circulation.
[12] D. Kereiakes,et al. Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. , 1996, The American journal of cardiology.
[13] A. Jawad,et al. Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. , 1995, American journal of clinical pathology.
[14] H. Weisman,et al. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. , 1995, Molecular immunology.
[15] J. Talley,et al. Heparin associated thrombocytopenia. , 1995, The Journal of the Arkansas Medical Society.
[16] Epic Investigators,et al. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.
[17] R. Califf,et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. , 1993, Journal of the American College of Cardiology.
[18] B. Coller. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. , 1985, The Journal of clinical investigation.
[19] Marshall A. Lichtman,et al. Commentary on and reprint of EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) Investigators, The, Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, in New England Journal of Medicine (1994) 330:956–961 , 2000 .
[20] J. Fareed,et al. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT. , 1999, Seminars in thrombosis and hemostasis.